Course Objectives
Upon completion of this course, participants should be able to:
- Analyze emerging structural, functional, and perfusion biomarkers associated with the development and progression of age-related macular degeneration (AMD).
- Interpret advances in multimodal retinal imaging and artificial intelligence–based approaches for assessing disease activity, progression risk, and treatment response in retinal disease.
- Evaluate evolving concepts in the pathobiology of nonexudative AMD and geographic atrophy, including mechanisms associated with retinal degeneration and perfusion abnormalities.
- Assess the strengths, limitations, and clinical relevance of novel clinical trial endpoints, outcome measures, and study designs used in retinal disease research.
- Review current evidence supporting approved therapies for geographic atrophy and incorporate real-world outcome data into treatment decision-making.
- Compare emerging pharmacologic, gene-based, cell-based, and regenerative therapies in development for nonexudative AMD.
- Evaluate investigational therapies and pivotal clinical trial results that may influence future management of neovascular AMD.
- Discuss advances in long-acting delivery systems, gene therapies, and next-generation anti-VEGF strategies designed to improve durability and visual outcomes in exudative retinal disease.
- Interpret multimodal retinal imaging, functional testing, and emerging artificial intelligence–based biomarkers to diagnose and assess retinal vascular disease
- Evaluate clinical trial and real-world evidence regarding the efficacy, safety, durability, and treatment burden of approved and investigational therapies for retinal vascular disease.
- Integrate biomarkers and patient-specific findings to develop evidence-based, individualized treatment strategies for retinal vascular disease.